LOCOID
LOE ApproachingNDATOPICALSOLUTION
Approved
Feb 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOCOID is a topical corticosteroid solution approved in 1987 for dermatological inflammation and pruritic conditions. The active ingredient is hydrocortisone butyrate, a potent topical steroid that reduces inflammation through glucocorticoid receptor agonism. It is indicated for inflammatory skin conditions requiring topical corticosteroid therapy.
LOE Approaching
As a mature product approaching loss of exclusivity with moderate competitive pressure (30%), the brand team likely focuses on defensive positioning and lifecycle management rather than growth expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LOCOID offers limited career growth due to zero linked job openings and approaching loss of exclusivity. Roles on this product are primarily defensive, focused on maintaining market share and managing transition to generic competition rather than innovation or expansion.
Field SalesBrand Manager
Worked on LOCOID at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.